Reuters -- Amylin Pharmaceuticals Inc said on Wednesday it expects to begin selling the long acting version of its Byetta diabetes drug this year and sees “a clear path to sustained profitability.”
Reuters -- Amylin Pharmaceuticals Inc said on Wednesday it expects to begin selling the long acting version of its Byetta diabetes drug this year and sees “a clear path to sustained profitability.”
